H.C. Wainwright Keeps a Buy Rating on Celyad (CYAD)


H.C. Wainwright analyst Edward White maintained a Buy rating on Celyad (CYAD) today and set a price target of $52. The company’s shares closed yesterday at $19.52.

According to TipRanks.com, White is a 5-star analyst with an average return of 15.5% and a 49.3% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Aileron Therapeutics Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Celyad with a $51 average price target, representing a 161.2% upside. In a report issued on May 9, William Blair also maintained a Buy rating on the stock.

See today’s analyst top recommended stocks >>

The company has a one-year high of $32.18 and a one-year low of $15.36. Currently, Celyad has an average volume of 3,702.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Celyad SA is a clinical-stage biopharmaceutical company, which engages in the development of cell-based therapies for the treatment of cancer. It operates through the following segments: Cardiology, Immuno-oncology, and Corporate. The Cardiology segment includes the company’s Cardiopoiesis, Corquest, and C-Cathez platforms.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts